blicly the results of any revisions to
these forward- looking statements to reflect events or circumstances
arising after the date hereof.
Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit
http://www.cardiumthx.com.
Cardium Therapeutics(TM), Corgentin(TM) and Generx(TM) are trademarks
of
Cardium Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
trademarks of the Tissue Repair Company.
InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM),
Accutrol(TM), CoolBlue(TM) and RapidBlue(TM)are trademarks of InnerCool
Therapies, Inc.
Cardium Therapeutics, Inc.
Three Months Ended
June 30,
(Unaudited)
Selected Condensed Consolidated 2008 2007
Operational Results
Revenues $626,841 $229,472
Cost of goods sold (314,254) (258,177)
Gross profit (loss) 312,587 (28,705)
Research and development 3,969,406 3,415,213
Selling, general and administrative 2,696,559 2,978,448
Amortization - Intangibles 197,414 207,043
Loss from operations (6,550,792) (6,629,409)
Interest income (expense), net (83,670) 228,228
Net loss $(6,634,462) $(6,401,181)
Net loss per common
share - basic and diluted $(0.15) $(0.16)
'/>"/>
SOURCE Cardium Therapeutics Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities2.
Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack3.
Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.4.
Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling5.
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates6.
Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant7.
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C8.
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE9.
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting10.
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study11.
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines